Research
Hormonal
New treatment approaches, including glucagon-like peptide-1 agonists, may be effective for weight loss in pregnant individuals.
Healthcare providers should consider new medical therapies for managing obesity in pregnant individuals.
StrongSupportsmedium confidence
We will describe new treatment approaches including glucagon-like peptide-1 agonists, which may be an effective strategy for achieving weight loss.
Why this rating
The claim is based on a review of existing literature.
Source
Treatment of Obesity Before, During, and After Pregnancy: Time for Obstetricians to Get Involved
Deborah Gustafson et al. · Obstetrical & Gynecological Survey · 2024
DOI 10.1097/ogx.0000000000001329
reviewCited 2×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →